share_log

ATyr Pharma Announces Research Study With Stanford Medicine Focusing On Understanding The Basic Mechanisms Of Immunosuppression In Glioblastoma Multiforme

Benzinga ·  Jul 30 08:14

aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has entered into a research agreement with Stanford Medicine. Michael Lim, M.D., Chair of the Department of Neurosurgery at Stanford Medicine, will serve as the principal investigator for the study. Dr. Lim's research focuses on understanding the basic mechanisms of immunosuppression in glioblastoma multiforme (GBM).

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment